Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Calgary

$105,000.00

Characterizing the mechanisms by which oncolytic viruses induce antitumour immunity

EF 2019-20

Résumé
Immunotherapy has revolutionized cancer care, in some cases generating cures in patients that have failed all other treatments. Our lab studies a new and exciting form of immunotherapy called oncolytic viruses (OVs). These are viruses that were originally designed to seek out and kill cancer cells in a patient while leaving normal cells untouched. However, it's now become clear that these viruses work primarily by stimulating the patient's own immune system to fight his or her cancer. How this occurs is not well understood. Currently, the belief in the field is that OVs must first infect the patient's cancer cells to generate an anticancer immune response. However, my research points towards a very different mechanism. I have found that in many cancer models, OVs can stimulate anticancer immunity and cause tumour regression without infecting cancer cells. Surprisingly, when this occurs, OVs readily infect certain immune cells in other organs such as the spleen and lymph nodes. These unexpected findings have prompted me to hypothesize that infection of immune cells is what instigates tumour regression, and that cancer cell infection is not required. To test this hypothesis, I will do two things. First, I will genetically engineer cancer cells that are resistant to infection by OVs. I will then treat mice bearing these infection-resistant tumours with OVs to determine whether cancer cell infection is required for OV therapy to work. Second, I will identify the infected immune cells that play a role in OV therapy and determine how they promote tumour regression. This research will greatly expand our understanding of how OVs work and has the potential to be paradigm-shifting in the field. Knowledge gained from these studies will allow for the development of new OV strains that leverage non-cancer cell infections to produce more effective anticancer immune responses. Ultimately, this may result in improved outcomes for patients receiving OV treatment for their cancer.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
417140
Name
Rajwani Jahanara
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing the mechanisms by which oncolytic viruses induce antitumour immunity
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Anticancer T Cells; Cancer Immunotherapy; Host-Virus Interactions; Oncolytic Viruses; Rhabdoviruses
Abstract
Immunotherapy has revolutionized cancer care, in some cases generating cures in patients that have failed all other treatments. Our lab studies a new and exciting form of immunotherapy called oncolytic viruses (OVs). These are viruses that were originally designed to seek out and kill cancer cells in a patient while leaving normal cells untouched. However, it's now become clear that these viruses work primarily by stimulating the patient's own immune system to fight his or her cancer. How this occurs is not well understood. Currently, the belief in the field is that OVs must first infect the patient's cancer cells to generate an anticancer immune response. However, my research points towards a very different mechanism. I have found that in many cancer models, OVs can stimulate anticancer immunity and cause tumour regression without infecting cancer cells. Surprisingly, when this occurs, OVs readily infect certain immune cells in other organs such as the spleen and lymph nodes. These unexpected findings have prompted me to hypothesize that infection of immune cells is what instigates tumour regression, and that cancer cell infection is not required. To test this hypothesis, I will do two things. First, I will genetically engineer cancer cells that are resistant to infection by OVs. I will then treat mice bearing these infection-resistant tumours with OVs to determine whether cancer cell infection is required for OV therapy to work. Second, I will identify the infected immune cells that play a role in OV therapy and determine how they promote tumour regression. This research will greatly expand our understanding of how OVs work and has the potential to be paradigm-shifting in the field. Knowledge gained from these studies will allow for the development of new OV strains that leverage non-cancer cell infections to produce more effective anticancer immune responses. Ultimately, this may result in improved outcomes for patients receiving OV treatment for their cancer.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rajwani, Jahanara
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~